CFO Dunn Gordon buys 122,221 QNRX shares at $0.45; holdings rise 423.6% on 5 prior well-timed buys at this ticker, cluster pattern active.
Dunn Gordon, CFO of Quoin Pharmaceuticals, purchased 122,221 shares at $0.45 on 2024-12-23, increasing his holdings by 423.6% from 28,856 to 151,077 shares. This buy occurs within a cluster: 3 other insiders also purchased within the past 14 days. More notably, Gordon's prior 5 open-market buys at QNRX were all well-timed, each generating positive 90-day returns ranging from +2900.0% to +3745.1%. His cross-ticker track record shows a 100% win rate on 90-day returns averaging +3387.2%. The current stock price of $19.25 is -89.3% from its 52-week high of $180.14, and the company reported a net loss of $-2,349,885.00 over the most recent full fiscal year. The confluence of a large concentrated buy by an executive with a documented history of well-timed accumulation at this specific ticker, combined with synchronized buying by other insiders, warrants investor attention to understand Gordon's rationale and to monitor whether this price action represents a reversal signal or reflects upcoming catalysts.